This is an old revision of this page, as edited by Beetstra (talk | contribs) at 10:07, 19 January 2011 (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: ChEMBL.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 10:07, 19 January 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: ChEMBL.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Combination of | |
|---|---|
| Imipenem | Carbapenem antibiotic |
| Cilastatin | Dehydropeptidase inhibitor |
| Clinical data | |
| Routes of administration | Intravenous, intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Imipenem/cilastatin (Primaxin) is a broad spectrum beta-lactam antibiotic containing equal quantities of imipenem and cilastatin. It is related to the penicillin/cephalosporin family of antibiotics but is classified as belonging to the carbapenem class.
Mechanism
It has the ability to kill a wide variety of bacteria. It works by interfering with their ability to form cell walls, and therefore the bacteria break up and die.
- Doripenem, the active cardiac agent, is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective); the metabolites can cause kidney damage.
- Administration. Primaxin FDA label, Food and Drug Administration. Oct 2006.</ref> It may be less likely to cause an allergic reaction in people who have had an allergic reaction to a penicillin in the past. It is particularly effective against Enterobacter species.
Marketing
Imipenem/cilastatin is marketed by Merck & Co. under the trade names Primaxin , Tienam and Zienam. The combination is also marketed by Ranbaxy Laboratories in India under the brand name Cilanem and by Nucleus as Thilia. Imipenem/cilastatin is marketed by Highnoon Laboratories Ltd. in Pakistan under the trade name Prepenem. Prepenem was launched by Highnoon in May 2007 and was the first generic brand after the research brand Tienam.